Drug intelligence / Profile preview

mRNA-SFTSV vaccine

Development stage: Preclinical
Lead developer: International Vaccine Institute
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

mRNA-SFTSV vaccine is a preclinical mRNA-based vaccine candidate being developed by Vernagen for the prevention of Severe Fever with Thrombocytopenia Syndrome (SFTS), a viral hemorrhagic fever caused by the SFTS virus (SFTSV). The vaccine utilizes mRNA technology to encode specific SFTSV antigens, which, upon administration, are translated by the host's cells to elicit a protective immune response. Development is currently in the preclinical animal efficacy stage, with testing conducted in collaboration with CB University in South Korea.

Other names: SFTS vaccine

Beyond the preview

Go deeper on mRNA-SFTSV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-SFTSV vaccine.

Explore the full profile